Notice to Readers: Manufacturer's Recall of Nasal Spray Contaminated with Burkholderia cepacia Complex
On March 24, this notice was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).
CDC has been notified of a voluntary recall of over-the-counter oxymetazoline HCl 0.05% nasal spray because of intrinsic contamination with Burkholderia cepacia complex. The nasal spray is distributed as "Major Twice-A-Day 12 Hour Nasal Spray." The manufacturer (Propharma Inc., Miami, Florida) has recalled lot no. K4496, released in November 2003, with an expiration date of October 2006.
Preliminary molecular epidemiology indicates that isolates related to the strain found in the nasal spray have
been recovered from patients in multiple states. Clinicians should be aware that patients using product from this lot number
might have been exposed to B. cepacia complex. Patients with underlying lung disease (especially cystic fibrosis) might be at increased risk for severe infections with B.
cepacia complex. Cases of B. cepacia complex infection or colonization associated with use of
this product should be reported to the local or state health department and CDC, telephone 800-893-0485.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.